EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation

Kristen Thane iD, Rebecca Voth, Rebecca Klee iD, Tobias Warnken iD, Victor Chukwu, Nicholas Frank iD

Journal of Veterinary Internal Medicine · 01.11.2025 · 39 (6)

DOI: 10.1111/jvim.70256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.11.2025. Verfasst von Kristen Thane und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Horse Diseases, Hyperinsulinism, Insulin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim Animal Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are promising treatments to manage hyperinsulinemia in horses with insulin dysregulation (ID). Hypothesis The SGLT2i velagliflozin decreases insulin concentration in horses with ID. Animals Privately-owned adult horses (n = 37) with laboratory-confirmed ID (low-dose oral sugar test insulin concentration > 75 μIU/mL).

Methods

Double-blind randomized placebo-controlled trial. Horses received placebo (n = 19) or velagliflozin 0.3 mg/kg PO q24h (n = 18) for 20 weeks (Study Period 1, SP1) immediately followed by a 20-week open-label trial where all animals received velagliflozin (SP2). Analysis of resting insulin, glucose, and triglyceride concentrations and body condition score (BCS) was performed between treatment groups and study periods using a Mann–Whitney U test. For SP1, analysis of changes in biochemical analytes over time was performed using generalized linear mixed effects models (GLMM). Data are reported as median (interquartile range).

Results

In SP1, GLMM indicated a significant effect of treatment on insulin concentration (71 [33–131] μIU/mL in horses receiving velagliflozin and 157 [82–298] μIU/mL in horses receiving placebo; p < 0.0001). The average (95% confidence interval [CI]) effect of velagliflozin treatment on insulin concentration was 155 (90–219) μIU/mL. Horses receiving placebo in SP1 had lower insulin (50 [26–99] μIU/mL) during SP2 (p < 0.0001). All horses experienced a transient increase in serum triglyceride concentration during velagliflozin treatment with no clinical abnormalities reported. In SP1, larger decreases in BCS occurred in horses receiving velagliflozin (median BCS 1 point lower than baseline; p = 0.02) than those receiving placebo.

Conclusions

Velagliflozin significantly decreased resting insulin concentrations in horses with ID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicHorse DiseasesHyperinsulinismInsulinSodium-Glucose Transporter 2 InhibitorsAnimalsFemaleMaleBlood GlucoseDouble-Blind MethodHorses

Stichwörter der Autor:innen

endocrinologyequine metabolic syndromeinsulin dysregulationlaminitisoral sugar test

Substanzen

Blood GlucoseBridged Bicyclo Compounds, HeterocyclicInsulinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts, USA.
  • Boehringer Ingelheim Animal Health USA, Duluth, Georgia, USA.
  • Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
  • College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi, USA.

ORCID-Profile: Kristen Thane, Rebecca Klee, Tobias Warnken, Nicholas Frank

Förderung

  • Boehringer Ingelheim Animal Health

Zitieren

APA

Thane, K., Voth, R., Klee, R., Warnken, T., Chukwu, V., & Frank, N. (2025). Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine, 39(6). https://doi.org/10.1111/jvim.70256

Vancouver

Thane K, Voth R, Klee R, Warnken T, Chukwu V, Frank N. Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation. Journal of Veterinary Internal Medicine. 2025;39(6). doi:10.1111/jvim.70256

BibTeX
@article{Thane2025,
  author = {Thane, Kristen and Voth, Rebecca and Klee, Rebecca and Warnken, Tobias and Chukwu, Victor and Frank, Nicholas},
  title = {Effects of the Sodium-Glucose Cotransporter-2 Inhibitor Velagliflozin on Insulin Concentrations in Horses With Insulin Dysregulation},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2025},
  volume = {39},
  number = {6},
  doi = {10.1111/jvim.70256}
}
Kostenlos starten →